By Korea Basic Science Institute
Cancer diagnosis, biomarker discovery, and multi-omics research Research on metabolic diseases and functional biomaterials Mass spectrometry-based proteomic analysis and disease mechanism research Characterization studies of next-generation biopharmaceuticals Integrated mass spectrometry platform for next-generation biopharmaceuticals and disease research Performs cancer diagnostics, precise characterization of next-generation biopharmaceuticals (e.g., ADCs), and biomaterial marker analysis by integrating high-resolution mass spectrometry with advanced data interpretation technologies Maximizes the efficiency and reproducibility of drug development through an integrated platform that connects sample preparation, mass spectrometry analysis, and data processing Integrated analytical workflow (Sample to Insight) 시료 전처리 및 정밀 질량분석-바이오단백질, ADC, PTM 단백질, 단일세포/공간 단백체 등 다양한 시료 전처리 및 정성〮정량분석수행 / 다차원 정량 분석법 (DDA, DIA, TMT, PRM, MRM) - 고해상도 분석기술, 비표지 및 표지 정량분석, 동위원소 표준시료를 활용한 정량분석 / AI 및 소프트웨어 기반 데이터 처리 - MS Fragger, DIA-NN, Spectronaut, GPA, pGlyco 등 분석법에 최적화 된 서치 엔진 활용 / 암 진단 및 바이오마커/멀티오믹스 - 엑소좀 분석과 PBNP-NLISA 기술을 활용한 난치성 암 조기 진단 및 표적발굴 / 차세대 바이오의약품 특성 분석 - 항체, ADC, 당단백질의 당쇄 이질성 및 이성질체 구조의 정밀 분석지원 Key data analysis software used across research fields. Analysis data type / Software used DDA data: Msfragger, MaxQuant, Proteome Discoverer DIA data: DIA-NN, Spectronaut Glycoprotein: GPA, pGlyco Biopharmaceuticals, antibodies, ADCs: UNIFI PRM & MRM: Skyline Cancer diagnosis, biomarker discovery, and multi-omics research Applies exosome multi-omics analysis technologies based on proteomics and exosome isolation techniques to develop diagnostic technologies for intractable cancers and to discover and validate cancer targets Development of a high-sensitivity and user-friendly PBNP-NLISA analytical method for early biomarker diagnosis using colorectal cancer and adenoma clinical samples Research on metabolic diseases and functional biomaterials Performs structural and functional studies by isolating metabolic disease marker compounds from functional biomaterials and analyzing them using MS/MS Mass spectrometry-based proteomic analysis and disease mechanism research Intracellular proteomic analysis for mass spectrometry-based drug development Spatial proteomics analysis using small tissue samples at the single-cell level Discovery of biomarkers through qualitative proteomic analysis of clinical samples (blood, tissue, urine) and enhanced quantification using isotope-labeled standard samples Investigation of disease mechanisms through mass spectrometry-based analysis of post-translational modifications (phosphorylation and glycosylation) in proteomics Characterization studies of next-generation biopharmaceuticals Characterization of glycan heterogeneity in glycoprotein-based biopharmaceuticals through mass spectrometry analysis Advancement of isomer separation and structural characterization of next-generation therapeutics by integrating high-resolution mass spectrometry with multidimensional separation techniques such as ion mobility Research Infrastructure Possesses analytical infrastructure that integrates high-resolution and multidimensional mass spectrometry (LC-MS, MALDI-MS, Orbitrap, Cyclic IMS, etc.) with AI-based data interpretation technologies to enhance precise characterization of next-generation biopharmaceuticals such as antibodies, ADCs, and gene therapies, thereby maximizing the efficiency, precision, and reproducibility of drug development The Biopharmaceutical Mass Spectrometry Research Unit (Cho Geon, Choi Jongsun, Jung Youngho, Lee Jooyeon, Yoon Sungho, Kim Minseon) has established an integrated analytical platform supporting biopharmaceutical characterization and proteomics analysis as well as academia–industry–research collaborations, thereby contributing to next-generation therapeutic development and rapid manufacturing while functioning as a global hub for biopharmaceutical analysis
